Stockscreener 앱 받기
0.4139
6.36%
-0.0281
시간 외 거래:
.42
0.0061
+1.47%
전일 마감가:
$0.442
열려 있는:
$0.45
하루 거래량:
172.78K
Relative Volume:
0.31
시가총액:
$8.44M
수익:
순이익/손실:
$-30.33M
주가수익비율:
-0.0148
EPS:
-28.0369
순현금흐름:
$-24.28M
1주 성능:
-13.16%
1개월 성능:
-42.11%
6개월 성능:
-84.20%
1년 성능:
-96.51%
1일 변동 폭
$0.41
$0.4531
1주일 범위
$0.41
$0.49
52주 변동 폭
$0.1614
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.4139 | 8.44M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
507.00 | 128.50B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
213.74 | 85.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
762.81 | 78.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.30 | 51.08B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.95 | 41.57B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech Shareholders Approve Key Annual Meeting Actions - The Globe and Mail
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - Yahoo! Finance Canada
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit - GlobeNewswire
Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX) - www.hastingsstargazette.com
Form 8-K Moleculin Biotech, Inc. For: Oct 05 - StreetInsider
Moleculin Biotech stock reaches 89-patient MIRACLE milestone2d4f8a6b-9c3e-4f1a-b7d2-5e8c0a6f3b91 - AD HOC NEWS
Price to earnings forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Certain Pre-Funded Warrants of Moleculin Biotech, Inc. are subject to a Lock-Up Agreement Ending on 3-OCT-2026. - marketscreener.com
Moleculin Biotech CS (MBRX-Q) Stock Price and News - The Globe and Mail
Moleculin completes enrollment in Annamycin AML trial Part A - Investing.com
Form 8K Moleculin Biotech Inc For: 29 September By Investing.com - Investing.com UK
Moleculin completes enrollment in Annamycin AML trial Part A By Investing.com - Investing.com Canada
Moleculin Biotech completes Part A enrollment in MIRACLE; 89 patients, Q1 2027 readout on track - TradingView
Moleculin Biotech Completes Enrollment in Part A of Phase - GlobeNewswire
A leukemia trial finished enrolling 89 people. Full results are expected in early 2027. - Stock Titan
Moleculin Biotech Reports Peer-Reviewed Cardiac Safety Analysis of Annamycin - Kalkine Media
Moleculin reports cardiac safety data for Annamycin in study - Investing.com
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine - GlobeNewswire Inc.
A review found no signs of heart damage in 90 patients given a cancer drug - Stock Titan
Moleculin Announces Publication of Peer-Reviewed Cardiac - globenewswire.com
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com Nigeria
Moleculin presents preclinical pancreatic cancer data at AACR - Investing.com
Form 8K Moleculin Biotech Inc For: 25 September By Investing.com - Investing.com UK
A cancer drug may help immune cells attack pancreatic tumors, early tests suggest. - Stock Titan
Moleculin Biotech, Inc. (MBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Moleculin Biotech (NASDAQ: MBRX) Obtains Mexican Patent No. 436849 and Issues 888,400 Shares via ATM Offering - Kalkine Media
Moleculin Biotech Announces Mexican Patent Approval and ATM Share Offering Completion - Kalkine Media
Moleculin Biotech (MBRX) Strengthens IP with Mexican Patent Amid Challenging Valuation - GuruFocus
Form 8K Moleculin Biotech Inc For: 23 September By Investing.com - Investing.com Canada
Moleculin receives Mexican patent for Annamycin formulation - Investing.com
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 - globenewswire.com
A drug formulation designed to reach lung tumors has Mexican patent protection through 2040. - Stock Titan
Moleculin Biotech stock falls 32.71 percent on September 21 - AD HOC NEWS
Form 8K Moleculin Biotech Inc For: 18 September By Investing.com - Investing.com Nigeria
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
Moleculin Biotech receives Nasdaq delisting notice after minimum bid price violation - Investing.com
Moleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold - Bitget
Moleculin to Showcase New Annamycin Data at AACR Conference - GlobeNewswire
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Australia
Moleculin Biotech at H.C. Wainwright conference: aml hope builds - Investing.com
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Canada
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
A biotech’s clinical update goes online before New York investor meetings - stocktitan.net
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
Moleculin Biotech (MBRX) Holds Above $0.77 as Biotech Sector Watches Key Resistance at $0.81Trend Following Picks - siam.in
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - ACCESS Newswire
Moleculin Biotech Updates Investors with New Presentation - TipRanks
Moleculin (NASDAQ: MBRX) posts investor presentation online - stocktitan.net
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.46%
자본화:
|
볼륨(24시간):